Vicus Capital Novartis Ag Transaction History

Vicus Capital

$1.28 Billion
Q3 2025

A detailed history of Vicus Capital transactions in Novartis Ag stock. As of the latest transaction made, Vicus Capital holds 2,936 shares of NVS stock, worth $386,230. This represents 0.03% of its overall portfolio holdings.

Number of Shares

2,936

Previous 2,936 -0.0%

Holding current value

$386,230

Previous $355,000 5.92%

% of portfolio

0.03%

Previous 0.03%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Jul 18, 2025	BUY	$101.96 - $121.01 $7,137 - $8,470	70 Added 2.44%	2,936 $355,000
Q3 2024 Oct 21, 2024	SELL	$106.13 - $120.89 $5,200 - $5,923	-49 Reduced 1.68%	2,866 $329,000
Q2 2024 Jul 23, 2024	SELL	$92.57 - $107.37 $25,086 - $29,097	-271 Reduced 8.51%	2,915 $310,000
Q1 2024 Apr 17, 2024	BUY	$95.27 - $108.47 $4,954 - $5,640	52 Added 1.66%	3,186 $308,000
Q4 2023 Feb 01, 2024	SELL	$92.27 - $101.54 $36,262 - $39,905	-393 Reduced 11.14%	3,134 $316,000

Q3 2023 Oct 23, 2023	BUY	$94.73 - $105.13 $45,754 - $50,777	483 Added 15.87%	3,527 $359,000
Q2 2023 Aug 17, 2023	SELL	$92.52 - $104.91 $57,639 - $65,358	-623 Reduced 16.99%	3,044 $307,000
Q1 2023 May 02, 2023	BUY	$80.03 - $92.81 $7,522 - $8,724	94 Added 2.63%	3,667 $337,000
Q4 2022 Feb 15, 2023	SELL	$75.55 - $92.52 $12,239 - $14,988	-162 Reduced 4.34%	3,573 $324,000
Q3 2022 Nov 08, 2022	SELL	$74.61 - $87.26 $24,322 - $28,446	-326 Reduced 8.03%	3,735 $284,000
Q2 2022 Aug 10, 2022	SELL	$80.52 - $93.75 $4,026 - $4,687	-50 Reduced 1.22%	4,061 $343,000
Q1 2022 May 11, 2022	SELL	$80.11 - $90.62 $1,842 - $2,084	-23 Reduced 0.56%	4,111 $361,000
Q4 2021 Feb 10, 2022	BUY	$79.7 - $88.13 $329,479 - $364,329	4,134 New	4,134 $353,000

Others Institutions Holding NVS

# of Institutions

1,599

Shares Held

137M

Call Options Held

1.53M

Put Options Held

2.22M

View Full List

About NOVARTIS AG

Ticker NVS
Exchange OTC
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,151,000,064
Market Cap $283B
Description
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatol...

More about NVS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vicus Capital, based on Form 13F filings with the SEC.

News

Stay updated on Vicus Capital with notifications on news.

Account